Загрузка...
Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma
BACKGROUND: The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated. OBJECTIVE: To determine primary tumor response to treatment with targe...
Сохранить в:
| Опубликовано в: : | Eur Urol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4378833/ https://ncbi.nlm.nih.gov/pubmed/20952123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2010.09.034 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|